MultiplexDX

Revolutionary Multiplex8+ diagnostics enables personalized cancer treatment

SK
CompaniesEquityComing soon

MultiplexDX

Closure

The investment opportunity is already closed for new investors who have not expressed their interest in investing before the end of the transition period under the ECSPR, which expired on 10. 11. 2023.

Investors who have expressed their interest in investing before this deadline are provided with online functions for further communication and administrative actions regarding this investment through the Crowdberry platform.

About the investment opportunity

MultiplexDX, a well-established and successful biotechnology company, has developed Multiplex8+, a unique and innovative diagnostic that combines unique scientific methods to effectively treat breast cancer.

After a successful round of investment on Crowdberry in 2018, MultiplexDX continued to develop this breakthrough diagnostic test and now comes not only with a new campaign, but also with proven results!

MultiplexDX has completed an important phase of development (extensive retrospective clinical validation) of the Multiplex8+ diagnostic test for breast cancer patients, improving the diagnosis of this cancer to even greater accuracy. This is extremely important for more effective and life-saving treatments. The company has been awarded a major European EIC Accelerator grant, with even industry experts stating that the diagnostic is revolutionary and has huge potential to fundamentally change the way that breast cancer is diagnosed and treated. It prepares each patient for highly precise and individualized treatment. The deployment of Multiplex8+ in clinical practice will help save many lives and save the health and social care system significant financial resources. 

The company has already sent the results of the diagnosis to the first patient, which has helped in the fight against this insidious disease. Based on the diagnostic results, a specific treatment was suggested – and after two cycles, the patient's metastases have completely disappeared. 

It is estimated that there are more than a million delayed diagnoses in Europe due to the COVID-19 pandemic, and subsequent late diagnoses are at more complicated and advanced stages of the disease. This is where accurate diagnosis can help, enabling targeted treatment and saving many lives.

This opens a new chapter not only for MultiplexDX itself, a company dedicated to the diagnosis and treatment of cancer, but also for investors in the biotech segment.

Multiplex8+ diagnostic test

To view this section, please register.

To view this section, please register.

MultiplexDX at a glance

To view this section, please register.

The company and its goals

To view this section, please register.

The product

To view this section, please register.

Tým

To view this section, please register.

Market and competition

To view this section, please register.

Risks

To view this section, please register.

Intent of investment

To view this section, please register.

For more detailed information on the market analysis and competitive environment, please refer to the investment information that follows the non-binding expression of interest.
More information
€7,500,000
Target amount
€5,000
Min. investment
30%+ p.a.
Required return
€0
Interest
€0
Confirmed
159
Investors

You cannot invest in this opportunity at the moment
Documents





1
Registration
Sign up to access public investment documents as well as events
2
Indication of interest
Non-binding, to access investment documentation
3
Investment confirmation
Confirm the amount of your investment, upload the documents and fill out your data
4
Preparation and signing of contracts
We prepare the contracts and send them to you by email for signing.
5
You become an investor
Transfer the money and become investor in the company